Xenon Pharmaceuticals develops therapeutics for neurological disorders in Canada. Pipeline includes XEN1101, a Kv7 potassium channel opener in Phase 3 trials for epilepsy and other disorders. XEN1101 also being developed for treatment of neurological disorders. Company has license and collaboration agreement with Neurocrine Biosciences. Agreement is for development of NBI-921352, a Nav1.6 sodium channel inhibitor. NBI-921352 in Phase 2 clinical trials for SCN8A developmental and epileptic encephalopathy and adult focal epilepsy. Xenon Pharmaceuticals was incorporated in 1996 and headquartered in Burnaby, Canada.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.5 |